ArticleFrontiers in psychiatry2025

Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system.

Duoqin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.